In the high-stakes world of medical education, the path to becoming a physician is paved with grueling exams, sleepless shifts, and a financial burden that often lasts well into a doctor’s professional career. Now, a new legal challenge is targeting the very architecture of that path. Dr. Kaitlin Buhrke, a general surgeon based in Phoenix, has initiated a proposed class-action lawsuit against the Association of American Medical Colleges (AAMC), alleging that the organization wields an illegal monopoly over the residency application process, effectively "gouging" doctors at the most vulnerable stage of their careers.
The lawsuit, filed in August, strikes at the heart of the Electronic Residency Application Service (ERAS). For decades, ERAS has served as the mandatory gateway for medical graduates seeking residency positions. Dr. Buhrke’s complaint argues that the AAMC has weaponized its dominance to impose exorbitant fees on applicants who have no viable alternatives, framing the organization’s conduct as a violation of federal antitrust law.
The Core Allegations: Profit Over Potential
At the center of the complaint is the assertion that the AAMC generates roughly $120 million in annual revenue from ERAS fees alone. With approximately 64,000 applicants participating in the cycle, the financial pressure is immense. Because residency placement is hyper-competitive, applicants are often forced to apply to dozens of programs to secure a single spot, driving the average cost per person to roughly $1,800.
Dr. Buhrke’s own experience highlights the systemic cost: she submitted 81 applications through the ERAS portal, incurring a total cost of $1,691. The lawsuit posits that these fees are not merely administrative costs but rather an extraction of wealth from young doctors, many of whom are already carrying six-figure student loan debt.
The complaint further alleges that the AAMC has actively stifled competition to maintain this revenue stream. Beyond the lack of market alternatives—ERAS currently faces only niche competition from platforms like ResidencyCAS and SF Match—the lawsuit claims the AAMC secured an equity stake in the competitor platform Thalamus specifically to neutralize it as a viable threat to their monopoly.
A Chronology of Legal Scrutiny
The challenge brought by Dr. Buhrke is not an isolated incident but part of a growing wave of legal and political pressure on the AAMC.
- The Early 2000s: The precedent for this tension was set in Jung v. AAMC, a landmark case where doctors alleged that the National Resident Matching Program (NRMP) suppressed physician salaries and mandated grueling working conditions. The case was ultimately neutralized when the AAMC successfully lobbied Congress to include an antitrust exemption for "the match" in a 2004 pension funding bill.
- The 2025 Surge: Legal momentum began to build significantly last year. The law firm Hilgers PLLC, representing Dr. Buhrke, filed a separate class-action suit alleging that the AAMC’s medical school application service, AMCAS, was similarly overcharging students.
- May 2025: A House Judiciary subcommittee held a pivotal hearing to question the validity of the 2004 antitrust exemption. Testimony revealed a sharp divide: some experts argued the exemption is a necessary guardrail against chaos in residency placement, while others decried it as a tool that prevents market competition and depresses physician wages.
- March 2026: The House Judiciary Committee released a scathing report characterizing the match system as a monopoly that actively harms patients by constraining the growth of the physician workforce.
- August 2026: Dr. Buhrke files the current class-action suit, bringing the focus directly onto the ERAS application platform.
The Economic and Educational Implications
The debate surrounding the AAMC’s role in medical education is as much about the future of healthcare as it is about antitrust law. Critics argue that by controlling the entry point to residency, the AAMC indirectly influences the physician pipeline. If applicants are discouraged by costs or if the match process itself is optimized for institutional convenience rather than candidate success, the ripple effects are felt in the accessibility of patient care.
Dr. Bryan Carmody, a well-known voice in medical education and an assistant professor at Eastern Virginia Medical School, notes that ERAS is the single largest revenue driver for the AAMC. He points out that while the recent pharmacy resident lawsuit—which challenged wage-fixing practices—was dismissed, it set a procedural standard for how these types of labor-market antitrust cases might be handled in the future.
However, the "antitrust exemption" remains the AAMC’s strongest shield. As established in the aftermath of Jung v. AAMC, the organization enjoys a degree of legislative protection that makes standard antitrust litigation exceptionally difficult. The AAMC maintains that its mission is to ensure a "fair, secure, and efficient application process," and they have signaled their intent to defend the current structure with vigor.
Official Responses and the Road Ahead
The AAMC has remained tight-lipped regarding the specifics of the pending litigation. In an emailed statement, the organization noted, "We remain committed to a fair, secure, and efficient application process for all residency and fellowship applicants and will vigorously defend this lawsuit."
Legal experts suggest that the AAMC will likely pursue a motion to dismiss, citing the existing legislative exemptions and the inherent complexity of the medical residency market. However, even if a dismissal is sought, the timeline for such a move is uncertain. The courts in Washington, D.C., are currently facing significant backlogs, meaning this legal battle could drag on for years. For context, the motion to dismiss the related AMCAS (medical school application) case, filed in late 2025, remains pending, indicating the slow pace of judicial resolution in these matters.
The Broader Antitrust Landscape
The scrutiny facing the AAMC is part of a wider trend in American law where federal agencies and courts are taking a more critical look at "special interest" exemptions. The House Judiciary Committee’s report from March 2026 was particularly pointed, stating: "The Match’s anticompetitive conduct is currently shielded from scrutiny by a special-interest antitrust exemption that allows it to harm the public while avoiding judicial oversight."
This sentiment reflects a shift in political appetite. Whether this will translate into a repeal of the 2004 exemption is unclear, but the mere existence of the legislative debate suggests that the AAMC’s long-standing status quo is no longer untouchable.
Conclusion: The Future of Physician Residency
The lawsuit filed by Dr. Buhrke is a high-stakes test of whether a professional association can maintain a near-total lock on an industry’s labor pipeline. For the thousands of medical students who must use ERAS every year, the case represents more than just a dispute over fees; it represents a struggle for transparency and fairness in the medical training system.
As the case moves through the court system, the medical community will be watching closely. If the court permits the case to proceed, it could force the AAMC to justify the financial structure of the residency process in a public forum, potentially leading to increased transparency or structural reform. Conversely, if the case is dismissed, the AAMC may retain its grip, but the pressure from the House Judiciary Committee and a growing coalition of critics suggests that the "Match" will remain a target for reform for the foreseeable future.
Ultimately, the resolution of this conflict will likely hinge on whether the judiciary views the AAMC as a necessary steward of a complex system, or as a commercial entity that has outgrown its regulatory boundaries at the expense of those it is meant to serve. Until then, residency applicants continue to pay the price—both figuratively and literally—to participate in a system that they argue is designed to prioritize the institution over the individual doctor.
